There are currently 2877 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
HPV Vaccine, Imiquimod, and Metformin Combination Trial
NCT06686043
Recruiting
The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are: Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or m... Read More
Gender:
FEMALE
Ages:
Between 18 years and 64 years
Trial Updated:
11/11/2024
Locations: Baylor St. Luke's Medical Center- Dan L. Duncan Comprehensive Cancer Center, Houston, Texas +1 locations
Conditions: Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Register for Updates
Neurophysiologic Biomarkers in Rett Syndrome
NCT05932589
Recruiting
The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are: * Do these biomarkers change during clinical changes in individuals with RTT? * Are biomarkers stable over time in clinically stable individuals? * Do these biomarkers correlate with severity of RTT? Participants will be asked to undergo an electroencephalogram (EEG) with measurements of Evoked Potentials (EP) to measure electrical activity... Read More
Gender:
FEMALE
Ages:
Between 1 year and 18 years
Trial Updated:
11/08/2024
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Rett Syndrome, RTT, Rett Syndrome, Atypical
Register for Updates
Clinical and Basic Investigations Into Congenital Disorders of Glycosylation
NCT04199000
Recruiting
The purpose of this research is to study the natural history of congenital disorders of glycosylation and its causes and treatments.
Gender:
ALL
Ages:
All
Trial Updated:
11/07/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Congenital Disorders of Glycosylation
Register for Updates
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
NCT05853783
Recruiting
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: MD Anderson Cancer Cetner, Houston, Texas +1 locations
Conditions: Mouth Diseases
Register for Updates
A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection
NCT06168669
Recruiting
Purpose: To validate the safety and effectiveness of xBar monitoring tool for detection of post-operative anastomotic leaks in subjects undergoing rectal/sigmoid resections with anastomosis. The clinical team is blinded to the leak detection of the xBar system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
11/03/2024
Locations: Houston Methodist, Houston, Texas
Conditions: Colorectal Surgery, Anastomotic Leak
Register for Updates
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
NCT06598007
Recruiting
This is an FIH, multicenter, open-label, dose escalation and dose expansion study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2a. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no available therapy (or patients are not candidates for such therapy) for the assessment of DLTs at up to 6 dose levels of CT3001. Phase 2a is a dose expansion study to evaluate the preliminary efficacy of CT3001 in pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study on TLC590 for Managing Postsurgical Pain
NCT06574269
Recruiting
This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/31/2024
Locations: Memorial Hermann Village, Houston, Texas
Conditions: Postsurgical Pain Management
Register for Updates
NAFLD Clinical Care Pathway
NCT06671886
Recruiting
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the burden of NAFLD and its complications among Veterans is substantial. However, most VA patients with NAFLD are undiagnosed and untreated, and their care is not consistent with practic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: NAFLD, MASLD
Register for Updates
Study of Individuals Affected With Hypoplasminogenemia
NCT03797495
Recruiting
This is an Investigator initiated retrospective and prospective single cohort study. The study will utilize an international registry and develop a specimen biobank to provide an improved understanding of the natural history of hyposplasminogenemia, to elucidate the heterogeneity of phenotypic expression, identify markers to predict disease course, and inform improved therapeutic modalities
Gender:
ALL
Ages:
All
Trial Updated:
10/30/2024
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Plasminogen Deficiency
Register for Updates
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Register for Updates
Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction
NCT06511232
Recruiting
The purpose of this study is to determine if intraosseous (IO) morphine decreases pain and post-operative opioid use in patients undergoing anterior cruciate ligament (ACL) reconstruction.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
10/30/2024
Locations: Houston Methodist Research Institute, Houston, Texas
Conditions: Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Register for Updates
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
NCT05184569
Recruiting
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/28/2024
Locations: Houston Methodist Hospital - Nantz National Alzheimer Center, Houston, Texas
Conditions: Semantic Dementia
Register for Updates